首页 > 最新文献

Canadian Journal of Infectious Diseases & Medical Microbiology最新文献

英文 中文
Antimicrobial Resistance of Listeria monocytogenes from Animal Foods to First- and Second-Line Drugs in the Treatment of Listeriosis from 2008 to 2021: A Systematic Review and Meta-Analysis. 2008年至2021年,动物食品中单核细胞增生李斯特菌对治疗李斯特菌病的一线和二线药物的耐药性:一项系统回顾和荟萃分析
IF 2.8 4区 医学 Q3 Medicine Pub Date : 2022-10-07 eCollection Date: 2022-01-01 DOI: 10.1155/2022/1351983
Jaqueline Oliveira Dos Reis, Bruno Serpa Vieira, Adelino Cunha Neto, Vinicius Silva Castro, Eduardo Eustáquio de Souza Figueiredo

First-line drugs for the treatment of listeriosis are the same around the world, but particular conditions might reduce their efficacy, including antimicrobial resistance. Therefore, this study aimed to verify, based on a systematic review and meta-analysis, whether the prevalence of antimicrobial resistance in Listeria monocytogenes from animal foods is higher for first- or second-line antimicrobials. From the total of 302 identified studies, 16 met all the eligibility criteria from 2008 to 2021 and were included in this meta-analysis. They comprised a dataset of 1152 L. monocytogenes isolates, obtained from different animal food products, food processing environment, and live animals. The included studies were developed in South America (n = 5), Europe (n = 4), Asia (n = 3), Africa (n = 2), and North America (n = 2), testing a total of 35 different antimicrobials, 11 of them classified as first-line drugs. Complete lack of antimicrobial resistance across the studies (all L. monocytogenes isolates tested as susceptible) was only observed for linezolid, while widespread antimicrobial resistance (all L. monocytogenes isolates tested resistant) was described for amoxicillin, benzylpenicillin, cefoxitin, fusidic acid, imipenem, sulfamethoxazole, and vancomycin. Overall, the meta-analysis results indicated no evidence that antimicrobial resistance in L. monocytogenes isolated from animal-based food is higher for first-line antimicrobials compared to second-line compounds (p=0.37). A greater volume of publication, together with better characterization of the isolates, is still needed for a more precise estimate of the real prevalence of antimicrobial resistance in L. monocytogenes.

治疗李斯特菌病的一线药物在世界各地都是相同的,但特殊情况可能会降低其疗效,包括抗菌素耐药性。因此,本研究旨在通过系统回顾和荟萃分析,验证来自动物性食品的单核细胞增生李斯特菌对一线或二线抗菌素的耐药性是否更高。从总共302项确定的研究中,有16项符合2008年至2021年的所有资格标准,并纳入本荟萃分析。他们的数据集包括1152株单核增生乳杆菌,从不同的动物食品、食品加工环境和活体动物中获得。纳入的研究分别在南美(n = 5)、欧洲(n = 4)、亚洲(n = 3)、非洲(n = 2)和北美(n = 2)开展,共测试了35种不同的抗菌素,其中11种被列为一线药物。在所有研究中(所有单核增生乳杆菌分离株检测为敏感)仅观察到对利奈唑胺完全缺乏抗菌素耐药性,而广泛的抗菌素耐药性(所有单核增生乳杆菌分离株检测为耐药)被描述为阿莫西林、青霉素、头孢西丁、福西地酸、亚胺培南、磺胺甲恶唑和万古霉素。总体而言,meta分析结果显示,没有证据表明从动物性食品中分离的单核增生乳杆菌对一线抗菌素的耐药性高于二线化合物(p=0.37)。为了更精确地估计单核增生乳杆菌中抗菌素耐药性的真实流行情况,仍然需要更多的出版物,以及更好地描述分离株。
{"title":"Antimicrobial Resistance of <i>Listeria monocytogenes</i> from Animal Foods to First- and Second-Line Drugs in the Treatment of Listeriosis from 2008 to 2021: A Systematic Review and Meta-Analysis.","authors":"Jaqueline Oliveira Dos Reis,&nbsp;Bruno Serpa Vieira,&nbsp;Adelino Cunha Neto,&nbsp;Vinicius Silva Castro,&nbsp;Eduardo Eustáquio de Souza Figueiredo","doi":"10.1155/2022/1351983","DOIUrl":"https://doi.org/10.1155/2022/1351983","url":null,"abstract":"<p><p>First-line drugs for the treatment of listeriosis are the same around the world, but particular conditions might reduce their efficacy, including antimicrobial resistance. Therefore, this study aimed to verify, based on a systematic review and meta-analysis, whether the prevalence of antimicrobial resistance in <i>Listeria monocytogenes</i> from animal foods is higher for first- or second-line antimicrobials. From the total of 302 identified studies, 16 met all the eligibility criteria from 2008 to 2021 and were included in this meta-analysis. They comprised a dataset of 1152 <i>L. monocytogenes</i> isolates, obtained from different animal food products, food processing environment, and live animals. The included studies were developed in South America (<i>n</i> = 5), Europe (<i>n</i> = 4), Asia (<i>n</i> = 3), Africa (<i>n</i> = 2), and North America (<i>n</i> = 2), testing a total of 35 different antimicrobials, 11 of them classified as first-line drugs. Complete lack of antimicrobial resistance across the studies (all <i>L. monocytogenes</i> isolates tested as susceptible) was only observed for linezolid, while widespread antimicrobial resistance (all <i>L. monocytogenes</i> isolates tested resistant) was described for amoxicillin, benzylpenicillin, cefoxitin, fusidic acid, imipenem, sulfamethoxazole, and vancomycin. Overall, the meta-analysis results indicated no evidence that antimicrobial resistance in <i>L. monocytogenes</i> isolated from animal-based food is higher for first-line antimicrobials compared to second-line compounds (<i>p</i>=0.37). A greater volume of publication, together with better characterization of the isolates, is still needed for a more precise estimate of the real prevalence of antimicrobial resistance in <i>L. monocytogenes</i>.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33518381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Molecular Assessment of Domain I of Apical Membrane Antigen I Gene in Plasmodium falciparum: Implications in Plasmodium Invasion, Taxonomy, Vaccine Development, and Drug Discovery. 恶性疟原虫顶端膜抗原I基因I结构域的分子鉴定:在疟原虫入侵、分类、疫苗开发和药物发现中的意义
IF 2.8 4区 医学 Q3 Medicine Pub Date : 2022-10-07 eCollection Date: 2022-01-01 DOI: 10.1155/2022/1419998
Che Roland Achungu, Damian Nota Anong, Robert Adamu Shey, Cevie Jesenta Tabe

Given its global morbidity and mortality rates, malaria continues to be a major public health concern. Despite significant progress in the fight against malaria, efforts to control and eradicate the disease globally are in jeopardy due to lack of a universal vaccine. The conserved short peptide sequences found in Domain I of Plasmodium falciparum apical membrane antigen 1 (PfAMA1), which are exposed on the parasite cell surface and in charge of Plasmodium falciparum invasion of host cells, make PfAMA1 a promising vaccine candidate antigen. The precise amino acids that make up these conserved short peptides are still unknown, and it is still difficult to pinpoint the molecular processes by which PfAMA1 interacts with the human host cell during invasion. The creation of a universal malaria vaccine based on the AMA1 antigen is challenging due to these knowledge limitations. This study used genome mining techniques to look for these particular short peptides in PfAMA1. Thirty individuals with Plasmodium falciparum malaria had blood samples taken using Whatman's filter papers. DNA from the parasite was taken out using the Chelex technique. Domain I of the Plasmodium falciparum AMA1 gene was amplified using nested polymerase chain reactions, and the amplified products were removed, purified, and sequenced. The DNA sequence generated was converted into the matching amino acid sequence using bioinformatic techniques. These amino acid sequences were utilized to search for antigenic epitopes, therapeutic targets, and conserved short peptides in Domain I of PfAMA1. The results of this investigation shed important light on the molecular mechanisms behind Plasmodium invasion of host cells, a potential PfAMA1 vaccine antigen sequence, and prospective malaria treatment options in the future. Our work offers fresh information on malaria medication and vaccine research that has not been previously discussed.

鉴于其全球发病率和死亡率,疟疾仍然是一个主要的公共卫生问题。尽管在防治疟疾方面取得了重大进展,但由于缺乏通用疫苗,全球控制和根除这一疾病的努力处于危险之中。恶性疟原虫根尖膜抗原1 (PfAMA1)结构域I中的保守短肽序列暴露在疟原虫细胞表面,负责恶性疟原虫对宿主细胞的侵袭,使PfAMA1成为一种有希望的疫苗候选抗原。构成这些保守短肽的精确氨基酸仍然未知,并且仍然难以确定PfAMA1在入侵过程中与人类宿主细胞相互作用的分子过程。由于这些知识限制,基于AMA1抗原的通用疟疾疫苗的研制具有挑战性。本研究使用基因组挖掘技术在PfAMA1中寻找这些特殊的短肽。30名恶性疟原虫疟疾患者使用Whatman的滤纸采集了血液样本。利用Chelex技术提取了寄生虫的DNA。采用巢式聚合酶链反应扩增恶性疟原虫AMA1基因的结构域I,并对扩增产物进行去除、纯化和测序。利用生物信息学技术将生成的DNA序列转化为匹配的氨基酸序列。这些氨基酸序列被用来寻找抗原表位、治疗靶点和PfAMA1结构域I中的保守短肽。这项研究的结果为疟原虫入侵宿主细胞的分子机制、潜在的PfAMA1疫苗抗原序列以及未来的疟疾治疗方案提供了重要的线索。我们的工作提供了以前没有讨论过的关于疟疾药物和疫苗研究的新信息。
{"title":"Molecular Assessment of Domain I of Apical Membrane Antigen I Gene in <i>Plasmodium falciparum</i>: Implications in <i>Plasmodium</i> Invasion, Taxonomy, Vaccine Development, and Drug Discovery.","authors":"Che Roland Achungu,&nbsp;Damian Nota Anong,&nbsp;Robert Adamu Shey,&nbsp;Cevie Jesenta Tabe","doi":"10.1155/2022/1419998","DOIUrl":"https://doi.org/10.1155/2022/1419998","url":null,"abstract":"<p><p>Given its global morbidity and mortality rates, malaria continues to be a major public health concern. Despite significant progress in the fight against malaria, efforts to control and eradicate the disease globally are in jeopardy due to lack of a universal vaccine. The conserved short peptide sequences found in Domain I of <i>Plasmodium falciparum</i> apical membrane antigen 1 (PfAMA1), which are exposed on the parasite cell surface and in charge of <i>Plasmodium falciparum</i> invasion of host cells, make PfAMA1 a promising vaccine candidate antigen. The precise amino acids that make up these conserved short peptides are still unknown, and it is still difficult to pinpoint the molecular processes by which PfAMA1 interacts with the human host cell during invasion. The creation of a universal malaria vaccine based on the AMA1 antigen is challenging due to these knowledge limitations. This study used genome mining techniques to look for these particular short peptides in PfAMA1. Thirty individuals with <i>Plasmodium falciparum</i> malaria had blood samples taken using Whatman's filter papers. DNA from the parasite was taken out using the Chelex technique. Domain I of the <i>Plasmodium falciparum</i> AMA1 gene was amplified using nested polymerase chain reactions, and the amplified products were removed, purified, and sequenced. The DNA sequence generated was converted into the matching amino acid sequence using bioinformatic techniques. These amino acid sequences were utilized to search for antigenic epitopes, therapeutic targets, and conserved short peptides in Domain I of PfAMA1. The results of this investigation shed important light on the molecular mechanisms behind <i>Plasmodium</i> invasion of host cells, a potential PfAMA1 vaccine antigen sequence, and prospective malaria treatment options in the future. Our work offers fresh information on malaria medication and vaccine research that has not been previously discussed.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33518380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Performance of Rapid Antigen Tests for the Detection of SARS-CoV-2 Infection in the Emergency Department and Community: A Retrospective Study. 快速抗原试验在急诊科和社区检测SARS-CoV-2感染的临床效果:回顾性研究
IF 2.8 4区 医学 Q3 Medicine Pub Date : 2022-10-06 eCollection Date: 2022-01-01 DOI: 10.1155/2022/9447251
Pei-Chin Lin, Hung-Pin Chiu, Fang-Yi Cheng, Chih-Chun Chang, Fang-Yeh Chu
Background Rapid antigen tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection have been authorized for emergency use (EUA); however, the performance has not been fully evaluated in clinical contexts. This study aimed to provide evidence regarding the diagnostic performance of SARS-CoV-2 rapid antigen tests compared with the real-time reverse transcription-polymerase chain reaction (RT-PCR) test in the emergency department (ED) and community. Methods Patients who underwent SARS-CoV-2 rapid antigen tests using the VTRUST COVID-19 Antigen Rapid Test (TD-4531) and real-time RT-PCR on the same day in the ED or community from May 24, 2021, to June 24, 2021, were examined. Results Paired nasopharyngeal swabs were collected from 4022 suspected COVID-19 patients: 800 in the ED and 3222 in the community. Overall, 62 (1.54%) tested positive, 13 tested indeterminate, and 3947 tested negative by real-time RT-PCR. The sensitivity and specificity of the antigen test were 51.61% and 99.44% (overall), 62.50% and 99.61% (ED), and 31.82% and 99.40% (community), respectively. There were 30 false negatives and 22 false positives. Among the false negatives, 16.67% had a cycle threshold (Ct) value of <25. Conclusion The VTRUST COVID-19 Antigen Rapid Test showed comparable specificity as real-time RT-PCR for the ED and community, but the sensitivity was relatively low, especially when the Ct value was >25. This test can be useful for the rapid identification of infected subjects in an epidemic situation.
背景:用于检测严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)的快速抗原试验已被批准用于紧急使用(EUA);然而,在临床环境下的表现尚未得到充分评估。本研究旨在为SARS-CoV-2快速抗原检测与实时逆转录聚合酶链反应(RT-PCR)检测在急诊科(ED)和社区的诊断效能提供证据。方法:对2021年5月24日至2021年6月24日在急诊科或社区当天使用VTRUST COVID-19抗原快速检测试剂盒(TD-4531)和实时RT-PCR进行SARS-CoV-2快速抗原检测的患者进行检测。结果:收集到疑似COVID-19患者配对鼻咽拭子4022例,其中急诊科800例,社区3222例。总的来说,62例(1.54%)检测为阳性,13例检测不确定,3947例检测为阴性。抗原检测的敏感性为51.61%、99.44%(总体),特异性为62.50%、99.61% (ED), 31.82%、99.40%(社区)。有30个假阴性和22个假阳性。结论:VTRUST COVID-19抗原快速检测对ED和社区的特异性与实时RT-PCR相当,但敏感性相对较低,特别是当Ct值>25时。在传染病流行的情况下,这一测试可用于快速识别受感染的受试者。
{"title":"Clinical Performance of Rapid Antigen Tests for the Detection of SARS-CoV-2 Infection in the Emergency Department and Community: A Retrospective Study.","authors":"Pei-Chin Lin,&nbsp;Hung-Pin Chiu,&nbsp;Fang-Yi Cheng,&nbsp;Chih-Chun Chang,&nbsp;Fang-Yeh Chu","doi":"10.1155/2022/9447251","DOIUrl":"https://doi.org/10.1155/2022/9447251","url":null,"abstract":"Background Rapid antigen tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection have been authorized for emergency use (EUA); however, the performance has not been fully evaluated in clinical contexts. This study aimed to provide evidence regarding the diagnostic performance of SARS-CoV-2 rapid antigen tests compared with the real-time reverse transcription-polymerase chain reaction (RT-PCR) test in the emergency department (ED) and community. Methods Patients who underwent SARS-CoV-2 rapid antigen tests using the VTRUST COVID-19 Antigen Rapid Test (TD-4531) and real-time RT-PCR on the same day in the ED or community from May 24, 2021, to June 24, 2021, were examined. Results Paired nasopharyngeal swabs were collected from 4022 suspected COVID-19 patients: 800 in the ED and 3222 in the community. Overall, 62 (1.54%) tested positive, 13 tested indeterminate, and 3947 tested negative by real-time RT-PCR. The sensitivity and specificity of the antigen test were 51.61% and 99.44% (overall), 62.50% and 99.61% (ED), and 31.82% and 99.40% (community), respectively. There were 30 false negatives and 22 false positives. Among the false negatives, 16.67% had a cycle threshold (Ct) value of <25. Conclusion The VTRUST COVID-19 Antigen Rapid Test showed comparable specificity as real-time RT-PCR for the ED and community, but the sensitivity was relatively low, especially when the Ct value was >25. This test can be useful for the rapid identification of infected subjects in an epidemic situation.","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33518384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Factors Influencing Survival Status of HIV/AIDS after HAART in Huzhou City, Eastern China. 湖州市艾滋病患者HAART治疗后生存状况的影响因素
IF 2.8 4区 医学 Q3 Medicine Pub Date : 2022-10-06 eCollection Date: 2022-01-01 DOI: 10.1155/2022/2787731
Meihua Jin, Zhongrong Yang, Jing Li, Xiaoqi Liu, Zhenqian Wu

Background: Highly active antiretroviral therapy (HAART) can effectively reduce the risk of death and opportunistic infections in patients with HIV/AIDS. The aim of this study was to analyse the survival status and its influencing factors in HIV/AIDS after HAART.

Methods: The data on patients' sociodemographic characteristics, treatment information, and follow-up results from the Information Management System of the Chinese Center for Disease Control and Prevention were obtained. Bivariate and stepwise multivariate Cox proportional hazards regression model analyses were performed.

Results: A total of 1812 participants were included in this study, of which 1716 were still alive (survival group) and 96 had died (death group). The results indicated that respondents who were elderly (HR = 1.053, 95% CI: 1.037-1.069, P < 0.01), who had heterosexual transmission (HR = 2.422, 95% CI: 1.314-4.465, P < 0.01) and whose current WHO clinical stage was stage III or IV (HR = 2.399, 95% CI: 1.215-4.735, P < 0.05) were more likely to have died; respondents whose baseline CD4+ T-lymphocyte count was equal to or more than 200 cells/μL (HR = 0.412, 95% CI: 0.275-0.616, P < 0.05) were unlikely to have died.

Conclusions: It is recommended that HAART be provided to HIV/AIDS patients at an early clinical stage and that the health services for HIV/AIDS patients after taking medicines be strengthened, which will help promote adherence to therapeutic regimens and improve quality of life.

背景:高效抗逆转录病毒治疗(HAART)可有效降低HIV/AIDS患者的死亡和机会性感染风险。本研究的目的是分析HAART治疗后HIV/AIDS患者的生存状况及其影响因素。方法:从中国疾病预防控制中心信息管理系统获取患者的社会人口学特征、治疗信息及随访结果。进行双变量和逐步多变量Cox比例风险回归模型分析。结果:本研究共纳入1812例受试者,其中1716例仍健在(生存组),96例已死亡(死亡组)。结果显示,老年人(HR = 1.053, 95% CI: 1.037 ~ 1.069, P < 0.01)、异性传播者(HR = 2.422, 95% CI: 1.314 ~ 4.465, P < 0.01)、who临床分期为III期或IV期者(HR = 2.399, 95% CI: 1.215 ~ 4.735, P < 0.05)的死亡风险较高;基线CD4+ t淋巴细胞计数≥200个/μL (HR = 0.412, 95% CI: 0.275 ~ 0.616, P < 0.05)的应答者不太可能死亡。结论:建议在临床早期阶段为艾滋病患者提供HAART治疗,并加强对服药后艾滋病患者的卫生服务,有助于提高患者对治疗方案的依从性,提高患者的生活质量。
{"title":"Factors Influencing Survival Status of HIV/AIDS after HAART in Huzhou City, Eastern China.","authors":"Meihua Jin,&nbsp;Zhongrong Yang,&nbsp;Jing Li,&nbsp;Xiaoqi Liu,&nbsp;Zhenqian Wu","doi":"10.1155/2022/2787731","DOIUrl":"https://doi.org/10.1155/2022/2787731","url":null,"abstract":"<p><strong>Background: </strong>Highly active antiretroviral therapy (HAART) can effectively reduce the risk of death and opportunistic infections in patients with HIV/AIDS. The aim of this study was to analyse the survival status and its influencing factors in HIV/AIDS after HAART.</p><p><strong>Methods: </strong>The data on patients' sociodemographic characteristics, treatment information, and follow-up results from the Information Management System of the Chinese Center for Disease Control and Prevention were obtained. Bivariate and stepwise multivariate Cox proportional hazards regression model analyses were performed.</p><p><strong>Results: </strong>A total of 1812 participants were included in this study, of which 1716 were still alive (survival group) and 96 had died (death group). The results indicated that respondents who were elderly (<i>HR</i> = 1.053, 95% <i>CI</i>: 1.037-1.069, <i>P</i> < 0.01), who had heterosexual transmission (<i>HR</i> = 2.422, 95% <i>CI</i>: 1.314-4.465, <i>P</i> < 0.01) and whose current WHO clinical stage was stage III or IV (<i>HR</i> = 2.399, 95% <i>CI</i>: 1.215-4.735, <i>P</i> < 0.05) were more likely to have died; respondents whose baseline CD4<sup>+</sup> T-lymphocyte count was equal to or more than 200 cells/<i>μ</i>L (<i>HR</i> = 0.412, 95% <i>CI</i>: 0.275-0.616, <i>P</i> < 0.05) were unlikely to have died.</p><p><strong>Conclusions: </strong>It is recommended that HAART be provided to HIV/AIDS patients at an early clinical stage and that the health services for HIV/AIDS patients after taking medicines be strengthened, which will help promote adherence to therapeutic regimens and improve quality of life.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33518383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Investigating Antimicrobial Resistance and ESBL Producing Gene in Klebsiella Isolates among Neonates and Adolescents in Southern Bangladesh. 调查孟加拉国南部新生儿和青少年克雷伯菌的抗菌素耐药性和产生ESBL的基因
IF 2.8 4区 医学 Q3 Medicine Pub Date : 2022-09-30 eCollection Date: 2022-01-01 DOI: 10.1155/2022/7071009
Afroza Akter Tanni, Nahid Sultana, Wazir Ahmed, Md Mahbub Hasan, Md Shakhawat Hossain, Sajjad Hossain Noyon, Md Mobarok Hossain, Adnan Mannan

Background: Multidrug-resistant (MDR) clones of Klebsiella pneumoniae (Kpn) have been increasingly documented in community-acquired and nosocomial infections all around the globe. Extended-spectrum β-lactamases (ESBLs) are a rapidly evolving group of β-lactamase enzymes derived from SHV genes by mutations. This research work aimed to investigate and analyze the widespread prevalence of Kpn antibiotic resistance in different areas of the southern part of Bangladesh.

Methods: This particular study was executed and implemented by using 501 clinical samples or isolates from two different hospitals in Chattogram. The disk diffusion method was used to detect Kpn's sensitivity to 16 antibiotics in a drug susceptibility test. By using the PCR technique, the widespread prevalence of antibiotic-resistant gene blaSHV-11 was studied. Sequencing along with phylogenetic analysis was utilized to verify isolates with the blaSHV-11 gene.

Results: Almost all of the Kpn isolates were spotted to be antibiotic-resistant. These Kpn isolates were resistant to β-lactams, aminoglycosides, and quinolones at high levels. The spatial analysis displayed that infections involving Kpn were more common in the urban areas (70%) than in the rural areas (30%). Neonates had substantially higher levels (p < 0.001) of resistance to multidrug than other age groups. Cefepime was identified as the most frequent antibiotic-resistant to all age groups (56.68%). The highest numbers of resistant isolates (36.92%) were found in urine samples. The ESBL gene blaSHV-11 was found in 38% isolates.

Conclusion: The significant frequency of MDR Kpn harboring β-lactamases and AMR genes strongly suggests the requirement to develop effective antimicrobial resistance control and prevention measures in Bangladesh.

背景:肺炎克雷伯菌(Klebsiella pneumoniae, Kpn)多药耐药(MDR)克隆在全球社区获得性和医院感染中越来越多地被记录在案。宽谱β-内酰胺酶(ESBLs)是一类由SHV基因突变而来的快速进化的β-内酰胺酶。这项研究工作旨在调查和分析在孟加拉国南部不同地区普遍存在的Kpn抗生素耐药性。方法:本研究采用Chattogram中两个不同医院的501个临床样本或分离物进行。采用纸片扩散法检测药敏试验中Kpn对16种抗生素的敏感性。采用PCR技术对blaSHV-11耐药基因的广泛流行情况进行了研究。利用测序和系统发育分析来验证携带blaSHV-11基因的分离株。结果:几乎所有的Kpn分离株均发现耐药。这些Kpn分离株对β-内酰胺类、氨基糖苷类和喹诺酮类药物具有高水平耐药性。空间分析显示,涉及Kpn的感染在城市地区(70%)比农村地区(30%)更常见。新生儿对多药耐药水平明显高于其他年龄组(p < 0.001)。头孢吡肟是所有年龄组最常见的耐药抗生素(56.68%)。尿标本中耐药菌株最多(36.92%)。在38%的分离株中发现了ESBL基因blaSHV-11。结论:含有β-内酰胺酶和AMR基因的MDR Kpn频率较高,提示孟加拉国有必要制定有效的抗微生物药物耐药性控制和预防措施。
{"title":"Investigating Antimicrobial Resistance and ESBL Producing Gene in <i>Klebsiella</i> Isolates among Neonates and Adolescents in Southern Bangladesh.","authors":"Afroza Akter Tanni,&nbsp;Nahid Sultana,&nbsp;Wazir Ahmed,&nbsp;Md Mahbub Hasan,&nbsp;Md Shakhawat Hossain,&nbsp;Sajjad Hossain Noyon,&nbsp;Md Mobarok Hossain,&nbsp;Adnan Mannan","doi":"10.1155/2022/7071009","DOIUrl":"https://doi.org/10.1155/2022/7071009","url":null,"abstract":"<p><strong>Background: </strong>Multidrug-resistant (MDR) clones of <i>Klebsiella pneumoniae</i> (<i>Kpn</i>) have been increasingly documented in community-acquired and nosocomial infections all around the globe. Extended-spectrum <i>β</i>-lactamases (ESBLs) are a rapidly evolving group of <i>β</i>-lactamase enzymes derived from SHV genes by mutations. This research work aimed to investigate and analyze the widespread prevalence of <i>Kpn</i> antibiotic resistance in different areas of the southern part of Bangladesh.</p><p><strong>Methods: </strong>This particular study was executed and implemented by using 501 clinical samples or isolates from two different hospitals in Chattogram. The disk diffusion method was used to detect <i>Kpn</i>'s sensitivity to 16 antibiotics in a drug susceptibility test. By using the PCR technique, the widespread prevalence of antibiotic-resistant gene bla<sub>SHV-11</sub> was studied. Sequencing along with phylogenetic analysis was utilized to verify isolates with the bla<sub>SHV-11</sub> gene.</p><p><strong>Results: </strong>Almost all of the <i>Kpn</i> isolates were spotted to be antibiotic-resistant. These <i>Kpn</i> isolates were resistant to <i>β</i>-lactams, aminoglycosides, and quinolones at high levels. The spatial analysis displayed that infections involving <i>Kpn</i> were more common in the urban areas (70%) than in the rural areas (30%). Neonates had substantially higher levels (<i>p</i> < 0.001) of resistance to multidrug than other age groups. Cefepime was identified as the most frequent antibiotic-resistant to all age groups (56.68%). The highest numbers of resistant isolates (36.92%) were found in urine samples. The ESBL gene bla<sub>SHV-11</sub> was found in 38% isolates.</p><p><strong>Conclusion: </strong>The significant frequency of MDR <i>Kpn</i> harboring <i>β</i>-lactamases and AMR genes strongly suggests the requirement to develop effective antimicrobial resistance control and prevention measures in Bangladesh.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33518385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiological Findings in SARS-CoV-2 Viral Pneumonia Compared to Other Viral Pneumonias: A Single-Centre Study. SARS-CoV-2病毒性肺炎与其他病毒性肺炎的影像学表现:一项单中心研究
IF 2.8 4区 医学 Q3 Medicine Pub Date : 2022-09-29 eCollection Date: 2022-01-01 DOI: 10.1155/2022/2826524
Rana Günöz Cömert, Eda Cingöz, Sevim Meşe, Görkem Durak, Atadan Tunaci, Ali Ağaçfidan, Mustafa Önel, Şükrü Mehmet Ertürk

Background: Thorax computed tomography (CT) imaging is widely used as a diagnostic method in the diagnosis of coronavirus disease 2019 (COVID-19)-related pneumonia. Radiological differential diagnosis and isolation of other viral agents causing pneumonia in patients have gained importance, particularly during the pandemic.

Aims: We aimed to investigate whether there is a difference between CT images from patients with COVID-19-associated pneumonia compared to CT images of patients with pneumonia due to other viral agents and which finding may be more effective in diagnosis. Study Design. The study included 249 adult patients with pneumonia identified by thorax CT examination and with a positive COVID-19 RT-PCR test compared to 94 patients diagnosed with non-COVID-19 pneumonia (viral PCR positive but no bacterial or fungal agents detected in other cultures) between 2015 and 2019. CT images were retrospectively analyzed using the PACS system. CT findings were evaluated by two radiologists with 5 and 20 years of experience, in a blinded fashion, and the outcome was decided by consensus.

Methods: Demographic data (age, gender, and known chronic disease) and CT imaging findings (percentage of involvement, number of lesions, distribution preference, dominant pattern, ground-glass opacity distribution pattern, nodule, tree in bud sign, interstitial changes, crazy paving sign, reversed halo sign, vacuolar sign, halo sign, vascular enlargement, linear opacities, traction bronchiectasis, peribronchial wall thickness, air trapping, pleural retraction, pleural effusion, pericardial effusion, cavitation, mediastinal/hilar lymphadenopathy, dominant lesion size, consolidation, subpleural curvilinear opacities, air bronchogram, and pleural thickening) of the patients were evaluated. CT findings were also evaluated with the RSNA consensus guideline and the CORADS scoring system. Data were divided into two main groups-non-COVID-19 and COVID-19 pneumonia-and compared statistically with chi-squared tests and multiple regression analysis of independent variables.

Results: RSNA and CORADS classifications of CT scan images were able to successfully differentiate between positive and negative COVID-19 pneumonia patients. Statistically significant differences were found between the two patient groups in various categories including the percentage of involvement, number of lesions, distribution preference, dominant pattern, nodule, tree in bud, interstitial changes, crazy paving, reverse halo vascular enlargement, peribronchial wall thickness, air trapping, pleural retraction, pleural/pericardial effusion, cavitation, and mediastinal/hilar lymphadenopathy (p < 0.01). Multiple linear regression analysis of independent variables found a significant effect in reverse halo sign (β = 0.097, p < 0.05) and pleural effusion (β = 10.631, p < 0.05) on C

背景:胸部计算机断层扫描(CT)作为一种诊断方法被广泛应用于2019冠状病毒病(COVID-19)相关肺炎的诊断。放射鉴别诊断和隔离引起患者肺炎的其他病毒制剂已变得非常重要,特别是在大流行期间。目的:我们旨在探讨covid -19相关性肺炎患者的CT图像与其他病毒制剂所致肺炎患者的CT图像是否存在差异,以及哪种发现可能更有效地诊断。研究设计。该研究纳入了2015年至2019年期间通过胸部CT检查确诊的249名成年肺炎患者,其中COVID-19 RT-PCR检测呈阳性,而非COVID-19肺炎(病毒PCR阳性,但在其他培养中未检测到细菌或真菌)的患者为94名。采用PACS系统对CT图像进行回顾性分析。CT结果由两名分别有5年和20年经验的放射科医生以盲法评估,结果由共识决定。方法:人口统计学资料(年龄、性别、已知慢性疾病)及CT影像表现(受累百分比、病变数量、分布偏好、优势型、毛玻璃样混浊分布、结节、芽状树征、间质改变、铺路性紊乱征、反晕征、空泡征、晕征、血管扩张、线状混浊、牵引性支气管扩张、支气管周围壁增厚、气陷、胸膜缩回、胸膜积液、心包积液、评估患者的空化、纵隔/肺门淋巴结病变、显性病变大小、实变、胸膜下曲线形影、支气管充气征和胸膜增厚。CT表现也用RSNA共识指南和CORADS评分系统进行评估。将数据分为非COVID-19和COVID-19肺炎两组,采用卡方检验和自变量多元回归分析进行统计学比较。结果:CT扫描图像的RSNA和CORADS分类能够成功区分COVID-19阳性和阴性肺炎患者。两组患者在受累百分率、病变数量、分布偏好、优势形态、结节、芽状树、间质改变、疯狂铺路、逆晕血管扩张、支气管周围壁厚、气陷、胸膜回缩、胸膜/心包积液、空化、纵隔/肺门淋巴结病变等各类别差异均有统计学意义(p < 0.01)。自变量多元线性回归分析发现,反晕征(β = 0.097, p < 0.05)和胸腔积液(β = 10.631, p < 0.05)对COVID-19肺炎患者有显著影响。结论:出现反晕、无胸腔积液是COVID-19肺炎的特征,是与非COVID-19肺炎鉴别的可靠诊断工具。
{"title":"Radiological Findings in SARS-CoV-2 Viral Pneumonia Compared to Other Viral Pneumonias: A Single-Centre Study.","authors":"Rana Günöz Cömert,&nbsp;Eda Cingöz,&nbsp;Sevim Meşe,&nbsp;Görkem Durak,&nbsp;Atadan Tunaci,&nbsp;Ali Ağaçfidan,&nbsp;Mustafa Önel,&nbsp;Şükrü Mehmet Ertürk","doi":"10.1155/2022/2826524","DOIUrl":"https://doi.org/10.1155/2022/2826524","url":null,"abstract":"<p><strong>Background: </strong>Thorax computed tomography (CT) imaging is widely used as a diagnostic method in the diagnosis of coronavirus disease 2019 (COVID-19)-related pneumonia. Radiological differential diagnosis and isolation of other viral agents causing pneumonia in patients have gained importance, particularly during the pandemic.</p><p><strong>Aims: </strong>We aimed to investigate whether there is a difference between CT images from patients with COVID-19-associated pneumonia compared to CT images of patients with pneumonia due to other viral agents and which finding may be more effective in diagnosis. <i>Study Design</i>. The study included 249 adult patients with pneumonia identified by thorax CT examination and with a positive COVID-19 RT-PCR test compared to 94 patients diagnosed with non-COVID-19 pneumonia (viral PCR positive but no bacterial or fungal agents detected in other cultures) between 2015 and 2019. CT images were retrospectively analyzed using the PACS system. CT findings were evaluated by two radiologists with 5 and 20 years of experience, in a blinded fashion, and the outcome was decided by consensus.</p><p><strong>Methods: </strong>Demographic data (age, gender, and known chronic disease) and CT imaging findings (percentage of involvement, number of lesions, distribution preference, dominant pattern, ground-glass opacity distribution pattern, nodule, tree in bud sign, interstitial changes, crazy paving sign, reversed halo sign, vacuolar sign, halo sign, vascular enlargement, linear opacities, traction bronchiectasis, peribronchial wall thickness, air trapping, pleural retraction, pleural effusion, pericardial effusion, cavitation, mediastinal/hilar lymphadenopathy, dominant lesion size, consolidation, subpleural curvilinear opacities, air bronchogram, and pleural thickening) of the patients were evaluated. CT findings were also evaluated with the RSNA consensus guideline and the CORADS scoring system. Data were divided into two main groups-non-COVID-19 and COVID-19 pneumonia-and compared statistically with chi-squared tests and multiple regression analysis of independent variables.</p><p><strong>Results: </strong>RSNA and CORADS classifications of CT scan images were able to successfully differentiate between positive and negative COVID-19 pneumonia patients. Statistically significant differences were found between the two patient groups in various categories including the percentage of involvement, number of lesions, distribution preference, dominant pattern, nodule, tree in bud, interstitial changes, crazy paving, reverse halo vascular enlargement, peribronchial wall thickness, air trapping, pleural retraction, pleural/pericardial effusion, cavitation, and mediastinal/hilar lymphadenopathy (<i>p</i> < 0.01). Multiple linear regression analysis of independent variables found a significant effect in reverse halo sign (<i>β</i> = 0.097, <i>p</i> < 0.05) and pleural effusion (<i>β</i> = 10.631, <i>p</i> < 0.05) on C","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33497350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies. 治疗 COVID-19 的新型药物设计:临床前研究的系统回顾
IF 2.6 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2022-09-25 eCollection Date: 2022-01-01 DOI: 10.1155/2022/2044282
Sarah Mousavi, Shima Zare, Mahmoud Mirzaei, Awat Feizi

Background: Since the beginning of the novel coronavirus (SARS-CoV-2) disease outbreak, there has been an increasing interest in discovering potential therapeutic agents for this disease. In this regard, we conducted a systematic review through an overview of drug development (in silico, in vitro, and in vivo) for treating COVID-19.

Methods: A systematic search was carried out in major databases including PubMed, Web of Science, Scopus, EMBASE, and Google Scholar from December 2019 to March 2021. A combination of the following terms was used: coronavirus, COVID-19, SARS-CoV-2, drug design, drug development, In silico, In vitro, and In vivo. A narrative synthesis was performed as a qualitative method for the data synthesis of each outcome measure.

Results: A total of 2168 articles were identified through searching databases. Finally, 315 studies (266 in silico, 34 in vitro, and 15 in vivo) were included. In studies with in silico approach, 98 article study repurposed drug and 91 studies evaluated herbal medicine on COVID-19. Among 260 drugs repurposed by the computational method, the best results were observed with saquinavir (n = 9), ritonavir (n = 8), and lopinavir (n = 6). Main protease (n = 154) following spike glycoprotein (n = 62) and other nonstructural protein of virus (n = 45) was among the most studied targets. Doxycycline, chlorpromazine, azithromycin, heparin, bepridil, and glycyrrhizic acid showed both in silico and in vitro inhibitory effects against SARS-CoV-2.

Conclusion: The preclinical studies of novel drug design for COVID-19 focused on main protease and spike glycoprotein as targets for antiviral development. From evaluated structures, saquinavir, ritonavir, eucalyptus, Tinospora cordifolia, aloe, green tea, curcumin, pyrazole, and triazole derivatives in in silico studies and doxycycline, chlorpromazine, and heparin from in vitro and human monoclonal antibodies from in vivo studies showed promised results regarding efficacy. It seems that due to the nature of COVID-19 disease, finding some drugs with multitarget antiviral actions and anti-inflammatory potential is valuable and some herbal medicines have this potential.

背景:自新型冠状病毒(SARS-CoV-2)疾病爆发以来,人们对发现该疾病的潜在治疗药物越来越感兴趣。为此,我们对治疗 COVID-19 的药物开发(硅学、体外和体内)进行了系统回顾:从 2019 年 12 月到 2021 年 3 月,我们在主要数据库(包括 PubMed、Web of Science、Scopus、EMBASE 和 Google Scholar)中进行了系统检索。使用了以下术语组合:冠状病毒、COVID-19、SARS-CoV-2、药物设计、药物开发、硅学、体外和体内。对每项结果指标的数据综合采用了叙事综合法作为定性方法:结果:通过检索数据库,共发现了 2168 篇文章。最后,共纳入 315 项研究(266 项硅学研究、34 项体外研究和 15 项体内研究)。在采用硅学方法的研究中,98篇文章研究了COVID-19的再利用药物,91篇研究评估了草药。在通过计算方法重新确定用途的 260 种药物中,结果最好的是沙奎那韦(9 例)、利托那韦(8 例)和洛匹那韦(6 例)。主要蛋白酶(n = 154)、尖峰糖蛋白(n = 62)和病毒的其他非结构蛋白(n = 45)是研究最多的靶点。多西环素、氯丙嗪、阿奇霉素、肝素、贝普利地尔和甘草酸对 SARS-CoV-2 均有抑制作用:针对 COVID-19 的新型药物设计的临床前研究主要以主要蛋白酶和尖峰糖蛋白作为抗病毒开发的靶点。从评估的结构来看,硅学研究中的沙奎那韦、利托那韦、桉树、椴树、芦荟、绿茶、姜黄素、吡唑和三唑衍生物,体外研究中的多西环素、氯丙嗪和肝素,以及体内研究中的人类单克隆抗体都显示出了良好的疗效。看来,由于 COVID-19 疾病的性质,寻找一些具有多靶点抗病毒作用和抗炎潜力的药物是很有价值的,而一些草药就具有这种潜力。
{"title":"Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies.","authors":"Sarah Mousavi, Shima Zare, Mahmoud Mirzaei, Awat Feizi","doi":"10.1155/2022/2044282","DOIUrl":"10.1155/2022/2044282","url":null,"abstract":"<p><strong>Background: </strong>Since the beginning of the novel coronavirus (SARS-CoV-2) disease outbreak, there has been an increasing interest in discovering potential therapeutic agents for this disease. In this regard, we conducted a systematic review through an overview of drug development (in silico, in vitro, and in vivo) for treating COVID-19.</p><p><strong>Methods: </strong>A systematic search was carried out in major databases including PubMed, Web of Science, Scopus, EMBASE, and Google Scholar from December 2019 to March 2021. A combination of the following terms was used: coronavirus, COVID-19, SARS-CoV-2, drug design, drug development, In silico, In vitro, and In vivo. A narrative synthesis was performed as a qualitative method for the data synthesis of each outcome measure.</p><p><strong>Results: </strong>A total of 2168 articles were identified through searching databases. Finally, 315 studies (266 in silico, 34 in vitro, and 15 in vivo) were included. In studies with in silico approach, 98 article study repurposed drug and 91 studies evaluated herbal medicine on COVID-19. Among 260 drugs repurposed by the computational method, the best results were observed with saquinavir (<i>n</i> = 9), ritonavir (<i>n</i> = 8), and lopinavir (<i>n</i> = 6). Main protease (<i>n</i> = 154) following spike glycoprotein (<i>n</i> = 62) and other nonstructural protein of virus (<i>n</i> = 45) was among the most studied targets. Doxycycline, chlorpromazine, azithromycin, heparin, bepridil, and glycyrrhizic acid showed both in silico and in vitro inhibitory effects against SARS-CoV-2.</p><p><strong>Conclusion: </strong>The preclinical studies of novel drug design for COVID-19 focused on main protease and spike glycoprotein as targets for antiviral development. From evaluated structures, saquinavir, ritonavir, eucalyptus, Tinospora cordifolia, aloe, green tea, curcumin, pyrazole, and triazole derivatives in in silico studies and doxycycline, chlorpromazine, and heparin from in vitro and human monoclonal antibodies from in vivo studies showed promised results regarding efficacy. It seems that due to the nature of COVID-19 disease, finding some drugs with multitarget antiviral actions and anti-inflammatory potential is valuable and some herbal medicines have this potential.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2022-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33490862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial. 评价乳酸菌菌株对幽门螺杆菌感染的潜在保护作用:一项随机、双盲、安慰剂对照试验。
IF 2.8 4区 医学 Q3 Medicine Pub Date : 2022-09-23 eCollection Date: 2022-01-01 DOI: 10.1155/2022/6432750
Shumin Wang, Meiyi Zhang, Leilei Yu, Fengwei Tian, Wenwei Lu, Gang Wang, Wei Chen, Jialin Wang, Qixiao Zhai

Background: The beneficial effects of probiotic supplementation standard antibiotic therapies for Helicobacter pylori infection have been verified, but the ability of probiotic monotherapy to eradicate H. pylori remains unclear.

Aim: To evaluate the accuracy and efficacy of specific Lactobacillus strains against H. pylori infection.

Methods: Seventy-eight patients with H. pylori infection were treated with strain L. crispatus G14-5M (L. crispatus CCFM1118) or L. helveticus M2-09-R02-S146 (L. helveticus CCFM1121) or L. plantarum CCFM8610 at a dose of 2 g twice daily for one month. 14C-urea breath test, the gastrointestinal symptom rating scale, serum pepsinogen concentrations, and serum cytokine concentrations of patients were measured at baseline and end-of-trial to analyze the effect of the Lactobacillus strains in eradicating H. pylori infection and reducing gastrointestinal discomfort in patients. In addition, the composition and abundance of the intestinal microbiota of patients were also measured at end-of-trial.

Results: The 14C-urea breath test value of the three Lactobacillus treatment groups had decreased significantly, and the eradication rate of H. pylori had increased by the end of the trial. In particular, the eradication rate in the G14-5M treatment group was significantly higher than the placebo group (70.59% vs. 15.38%, P=0.0039), indicating that one-month administration of the G14-5M regimen was sufficient to eradicate H. pylori infection. The ingestion of Lactobacillus strains also ameliorated the gastrointestinal symptom rating scale scores, and the serum interleukin-8 concentrations of H. pylori-infected patients appeared to modulate the gut microbiota of patients. However, none of the Lactobacillus strains had a significant effect on general blood physiological characteristics, serum tumor necrosis factor α concentrations, or serum pepsinogen concentrations in the patients.

Conclusion: Three Lactobacillus strains significantly alleviate the gastrointestinal discomfort and the gastric inflammatory response of H. pylori-infected patients. The activity of probiotics in eradicating H. pyloriinfection may be species/strain specific.

背景:益生菌补充标准抗生素治疗幽门螺杆菌感染的有益效果已得到证实,但益生菌单药治疗根除幽门螺杆菌的能力尚不清楚。目的:评价特异性乳酸菌对幽门螺杆菌感染的准确性和疗效。方法:78例幽门螺杆菌感染患者分别用菌株L. crispatus G14-5M (L. crispatus CCFM1118)或L. helveticus M2-09-R02-S146 (L. helveticus CCFM1121)或L. plantarum CCFM8610治疗,剂量为2g,每日2次,疗程1个月。在基线和试验结束时测定患者的14c -尿素呼气试验、胃肠道症状评定量表、血清胃蛋白酶原浓度和血清细胞因子浓度,分析乳杆菌菌株对根除幽门螺杆菌感染和减轻患者胃肠道不适的作用。此外,在试验结束时也测量了患者肠道微生物群的组成和丰度。结果:试验结束时,3个乳杆菌处理组的14c -尿素呼气试验值明显降低,幽门螺杆菌根除率提高。特别是,G14-5M治疗组的根除率显著高于安慰剂组(70.59% vs. 15.38%, P=0.0039),说明G14-5M方案给予1个月的治疗足以根除幽门螺杆菌感染。乳酸菌菌株的摄入也改善了胃肠道症状评分量表得分,幽门螺杆菌感染患者的血清白细胞介素-8浓度似乎可以调节患者的肠道微生物群。然而,没有一种乳酸菌菌株对患者的一般血液生理特征、血清肿瘤坏死因子α浓度或血清胃蛋白酶原浓度有显著影响。结论:3株乳酸菌可显著缓解幽门螺旋杆菌感染患者的胃肠道不适和胃炎症反应。益生菌在根除幽门螺杆菌感染中的活性可能是种/菌株特异性的。
{"title":"Evaluation of the Potential Protective Effects of <i>Lactobacillus</i> Strains against <i>Helicobacter pylori</i> Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial.","authors":"Shumin Wang,&nbsp;Meiyi Zhang,&nbsp;Leilei Yu,&nbsp;Fengwei Tian,&nbsp;Wenwei Lu,&nbsp;Gang Wang,&nbsp;Wei Chen,&nbsp;Jialin Wang,&nbsp;Qixiao Zhai","doi":"10.1155/2022/6432750","DOIUrl":"https://doi.org/10.1155/2022/6432750","url":null,"abstract":"<p><strong>Background: </strong>The beneficial effects of probiotic supplementation standard antibiotic therapies for <i>Helicobacter pylori</i> infection have been verified, but the ability of probiotic monotherapy to eradicate <i>H. pylori</i> remains unclear.</p><p><strong>Aim: </strong>To evaluate the accuracy and efficacy of specific <i>Lactobacillus</i> strains against <i>H. pylori</i> infection.</p><p><strong>Methods: </strong>Seventy-eight patients with <i>H. pylori</i> infection were treated with strain <i>L. crispatus</i> G14-5M (<i>L. crispatus</i> CCFM1118) or <i>L. helveticus</i> M2-09-R02-S146 (<i>L. helveticus</i> CCFM1121) or <i>L. plantarum</i> CCFM8610 at a dose of 2 g twice daily for one month. <sup>14</sup>C-urea breath test, the gastrointestinal symptom rating scale, serum pepsinogen concentrations, and serum cytokine concentrations of patients were measured at baseline and end-of-trial to analyze the effect of the <i>Lactobacillus</i> strains in eradicating <i>H. pylori</i> infection and reducing gastrointestinal discomfort in patients. In addition, the composition and abundance of the intestinal microbiota of patients were also measured at end-of-trial.</p><p><strong>Results: </strong>The <sup>14</sup>C-urea breath test value of the three <i>Lactobacillus</i> treatment groups had decreased significantly, and the eradication rate of <i>H. pylori</i> had increased by the end of the trial. In particular, the eradication rate in the G14-5M treatment group was significantly higher than the placebo group (70.59% vs. 15.38%, <i>P</i>=0.0039), indicating that one-month administration of the G14-5M regimen was sufficient to eradicate <i>H. pylori</i> infection. The ingestion of <i>Lactobacillus</i> strains also ameliorated the gastrointestinal symptom rating scale scores, and the serum interleukin-8 concentrations of <i>H. pylori</i>-infected patients appeared to modulate the gut microbiota of patients. However, none of the <i>Lactobacillus</i> strains had a significant effect on general blood physiological characteristics, serum tumor necrosis factor <i>α</i> concentrations, or serum pepsinogen concentrations in the patients.</p><p><strong>Conclusion: </strong>Three <i>Lactobacillus</i> strains significantly alleviate the gastrointestinal discomfort and the gastric inflammatory response of <i>H. pylori</i>-infected patients. The activity of probiotics in eradicating <i>H. pylori</i>infection may be species/strain specific.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33487601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Prevalence, Antimicrobial Resistance, and Associated Factors of Streptococcus pneumoniae Colonization Rate among Old-Age Patients with Respiratory Tract Infection Attending Sheik Hassan Yebere Referral and Karamara General Hospitals, Jigjiga, Ethiopia. 埃塞俄比亚吉吉加谢赫·哈桑·耶贝尔转诊医院和卡拉马拉综合医院呼吸道感染老年患者肺炎链球菌定植率的流行、耐药性及相关因素
IF 2.8 4区 医学 Q3 Medicine Pub Date : 2022-09-23 eCollection Date: 2022-01-01 DOI: 10.1155/2022/9338251
Surafel Mekuria, Ayichew Seyoum, Zerihun Ataro, Tigist Abebe, Kedir Urgessa

Background: Streptococcus pneumoniae is part of the normal flora of the upper respiratory tract of humans. Colonization of the upper respiratory tract (carriage of pneumococcus) by S. pneumoniae is considered a prerequisite for pneumococcal infection. It is the major cause of respiratory tract infection and frequent cause of physician visits, hospitalization, and death among old-aged patients because of their low immunity status. However, data on S. pneumoniae among old-aged patients in eastern Ethiopia are limited. This study was undertaken to determine the prevalence, antimicrobial resistance, and associated factor of S. pneumoniae colonization among old-aged patients.

Method: A health facility-based cross-sectional study was conducted from 1 March to 15 April 2020, at Sheik Hassan Yebere Referral and Karamara General Hospitals, Jigjiga, eastern Ethiopia. A total of 188 individuals greater than or equal to 60 years suspected of both upper and lower respiratory tract infections were included. Sociodemographic, behavioral, living conditions, and clinical data were collected by trained data collectors. Sputum samples were collected and examined for S. pneumoniae using the culture and biochemical tests as per the standard procedures. The Kirby-Bauer disk diffusion method was used for antimicrobial susceptibility testing. The data were entered on Epi-data version 3.1, and frequencies, crude odds ratio, and adjusted odds ratio were analyzed using SPSS version 20.

Results: The prevalence of S. pneumoniae colonization rate among old-aged patients was 13.8% (26/188) (95% CI: 9.6-19.1). Smoking (AOR = 3.3; 95% CI: 1.3-8.3), upper airway problems (AOR = 4.1; 95% CI: 1.1-15), and asthma disease (AOR = 3.1; 95% CI: 1.1-8.9) were the factors associated with S. pneumoniae colonization. The isolated organisms showed high antimicrobial resistance to trimethoprim-sulphamethoxazole (n = 12, 46.2%), tetracycline (n = 11, 42.3%), and ampicillin (n = 9, 34.6%).

Conclusion: This study showed that high prevalence of S. pneumoniae and antimicrobial resistance for trimethoprim-sulphamethoxazole, tetracycline, and ampicillin when compared to similar studies. Cigarette smoking, having upper airway problem, and asthma disease were factors associated with S. pneumoniae colonization. The provision of pneumococci conjugate vaccination and avoiding smoking are highly recommended for old aged in the community.

背景:肺炎链球菌是人类上呼吸道正常菌群的一部分。肺炎链球菌在上呼吸道的定植(携带肺炎球菌)被认为是肺炎球菌感染的先决条件。它是引起呼吸道感染的主要原因,也是老年人因免疫力低下而就诊、住院和死亡的常见原因。然而,埃塞俄比亚东部老年患者中肺炎链球菌的数据有限。本研究旨在确定老年患者中肺炎链球菌定植的患病率、抗菌素耐药性和相关因素。方法:于2020年3月1日至4月15日在埃塞俄比亚东部吉吉加的谢赫·哈桑·耶贝尔转诊医院和卡拉马拉总医院进行了一项基于卫生设施的横断面研究。共纳入188名年龄大于或等于60岁的疑似上呼吸道和下呼吸道感染患者。社会人口学、行为、生活条件和临床数据由训练有素的数据收集人员收集。根据标准程序收集痰样本并使用培养和生化试验检查肺炎链球菌。采用Kirby-Bauer纸片扩散法进行药敏试验。使用Epi-data 3.1版本录入数据,使用SPSS 20版本对频率、粗优势比和调整优势比进行分析。结果:老年患者肺炎链球菌定殖率为13.8% (26/188)(95% CI: 9.6 ~ 19.1)。吸烟(AOR = 3.3;95% CI: 1.3-8.3),上呼吸道问题(AOR = 4.1;95% CI: 1.1-15)和哮喘(AOR = 3.1;95% CI: 1.1-8.9)是肺炎链球菌定植的相关因素。分离出的细菌对甲氧苄啶-磺胺甲恶唑(n = 12, 46.2%)、四环素(n = 11, 42.3%)和氨苄西林(n = 9, 34.6%)具有较高的耐药性。结论:本研究显示,与类似研究相比,肺炎链球菌的患病率较高,并且对甲氧苄氨嘧啶-磺胺甲恶唑、四环素和氨苄西林耐药。吸烟、上呼吸道问题和哮喘是肺炎链球菌定植的相关因素。强烈建议社区老年人接种肺炎球菌结合疫苗并避免吸烟。
{"title":"Prevalence, Antimicrobial Resistance, and Associated Factors of <i>Streptococcus pneumoniae</i> Colonization Rate among Old-Age Patients with Respiratory Tract Infection Attending Sheik Hassan Yebere Referral and Karamara General Hospitals, Jigjiga, Ethiopia.","authors":"Surafel Mekuria,&nbsp;Ayichew Seyoum,&nbsp;Zerihun Ataro,&nbsp;Tigist Abebe,&nbsp;Kedir Urgessa","doi":"10.1155/2022/9338251","DOIUrl":"https://doi.org/10.1155/2022/9338251","url":null,"abstract":"<p><strong>Background: </strong><i>Streptococcus pneumoniae</i> is part of the normal flora of the upper respiratory tract of humans. Colonization of the upper respiratory tract (carriage of pneumococcus) by <i>S. pneumoniae</i> is considered a prerequisite for pneumococcal infection. It is the major cause of respiratory tract infection and frequent cause of physician visits, hospitalization, and death among old-aged patients because of their low immunity status. However, data on <i>S. pneumoniae</i> among old-aged patients in eastern Ethiopia are limited. This study was undertaken to determine the prevalence, antimicrobial resistance, and associated factor of <i>S. pneumoniae</i> colonization among old-aged patients.</p><p><strong>Method: </strong>A health facility-based cross-sectional study was conducted from 1 March to 15 April 2020, at Sheik Hassan Yebere Referral and Karamara General Hospitals, Jigjiga, eastern Ethiopia. A total of 188 individuals greater than or equal to 60 years suspected of both upper and lower respiratory tract infections were included. Sociodemographic, behavioral, living conditions, and clinical data were collected by trained data collectors. Sputum samples were collected and examined for <i>S. pneumoniae</i> using the culture and biochemical tests as per the standard procedures. The Kirby-Bauer disk diffusion method was used for antimicrobial susceptibility testing. The data were entered on Epi-data version 3.1, and frequencies, crude odds ratio, and adjusted odds ratio were analyzed using SPSS version 20.</p><p><strong>Results: </strong>The prevalence of <i>S. pneumoniae</i> colonization rate among old-aged patients was 13.8% (26/188) (95% CI: 9.6-19.1). Smoking (AOR = 3.3; 95% CI: 1.3-8.3), upper airway problems (AOR = 4.1; 95% CI: 1.1-15), and asthma disease (AOR = 3.1; 95% CI: 1.1-8.9) were the factors associated with <i>S. pneumoniae</i> colonization. The isolated organisms showed high antimicrobial resistance to trimethoprim-sulphamethoxazole (<i>n</i> = 12, 46.2%), tetracycline (<i>n</i> = 11, 42.3%), and ampicillin (<i>n</i> = 9, 34.6%).</p><p><strong>Conclusion: </strong>This study showed that high prevalence of <i>S. pneumoniae</i> and antimicrobial resistance for trimethoprim-sulphamethoxazole, tetracycline, and ampicillin when compared to similar studies. Cigarette smoking, having upper airway problem, and asthma disease were factors associated with <i>S. pneumoniae</i> colonization. The provision of pneumococci conjugate vaccination and avoiding smoking are highly recommended for old aged in the community.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33487183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Xiang Qin Kang Gan Granules Treated the Human Coronavirus 229E Induced Pneumonia with Damp-Heat Syndrome in Mice. 香芹康肝颗粒治疗人冠状病毒229E诱导的小鼠肺炎湿热证。
IF 2.8 4区 医学 Q3 Medicine Pub Date : 2022-09-23 eCollection Date: 2022-01-01 DOI: 10.1155/2022/7609550
Fang Cao, Zhaoheng Liu, Qingxun Hao, Ronghua Zhao, Lei Bao, Xiaolan Cui, Yang Jiao

Coronavirus disease 2019 (COVID-19), which causes severe respiratory illness, was first reported in Wuhan, China. The etiology of the disease is a new novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was reported to share the same origin as SARS-CoV, causing severe public health events in 2002. Unlike the SARS-CoV, which was conquered in the early summer of 2003, this virus was still contagious widely and reached a pandemic level. It can still spread fast even if the season's temperature is raised. Here, we made a model of pneumonia of human coronavirus 229E (HCoV-229E) with damp-heat syndrome treated by Xiangqin Kanggan granules to find a new medicine for treating these kinds of infectious diseases coronaviruses induced.

引起严重呼吸道疾病的冠状病毒病2019 (COVID-19)首次在中国武汉报告。该病的病因是一种名为“严重急性呼吸综合征冠状病毒2型”(SARS-CoV-2)的新型冠状病毒,据报道该病毒与SARS-CoV同源,在2002年引发了严重的公共卫生事件。与2003年初夏被征服的sars冠状病毒不同,这种病毒仍然具有广泛的传染性,并达到了大流行的程度。即使季节温度升高,它仍然可以快速传播。本研究以香芩康肝颗粒治疗人冠状病毒感染的229E型肺炎(HCoV-229E)湿热证为模型,寻求治疗冠状病毒引起的这类传染病的新药。
{"title":"Xiang Qin Kang Gan Granules Treated the Human Coronavirus 229E Induced Pneumonia with Damp-Heat Syndrome in Mice.","authors":"Fang Cao,&nbsp;Zhaoheng Liu,&nbsp;Qingxun Hao,&nbsp;Ronghua Zhao,&nbsp;Lei Bao,&nbsp;Xiaolan Cui,&nbsp;Yang Jiao","doi":"10.1155/2022/7609550","DOIUrl":"https://doi.org/10.1155/2022/7609550","url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19), which causes severe respiratory illness, was first reported in Wuhan, China. The etiology of the disease is a new novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was reported to share the same origin as SARS-CoV, causing severe public health events in 2002. Unlike the SARS-CoV, which was conquered in the early summer of 2003, this virus was still contagious widely and reached a pandemic level. It can still spread fast even if the season's temperature is raised. Here, we made a model of pneumonia of human coronavirus 229E (HCoV-229E) with damp-heat syndrome treated by Xiangqin Kanggan granules to find a new medicine for treating these kinds of infectious diseases coronaviruses induced.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33487599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Canadian Journal of Infectious Diseases & Medical Microbiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1